When Will PYC Therapeutics Limited (ASX:PYC) Become Profitable?
Simply Wall St
Thu, January 15, 2026 at 8:34 PM EST
3 min read
In this article:
We feel now is a pretty good time to analyse PYC Therapeutics Limited's (ASX:PYC) business as it appears the company may be on the cusp of a considerable accomplishment. PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The AU$994m market-cap company announced a latest loss of AU$50m on 30 June 2025 for its most recent financial year result. As path to profitability is the topic on PYC Therapeutics' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
According to the 4 industry analysts covering PYC Therapeutics, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2027, before generating positive profits of AU$100m in 2028. The company is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 28% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
Underlying developments driving PYC Therapeutics' growth isn’t the focus of this broad overview, but, take into account that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
Check out our latest analysis for PYC Therapeutics
One thing we’d like to point out is that PYC Therapeutics has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
There are key fundamentals of PYC Therapeutics which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at PYC Therapeutics, take a look at PYC Therapeutics' company page on Simply Wall St. We've also compiled a list of essential factors you should look at:
Story Continues
-
Valuation: What is PYC Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether PYC Therapeutics is currently mispriced by the market.
-
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on PYC Therapeutics’s board and the CEO’s background.
-
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments